KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Gross Profit (2016 - 2025)

AbbVie (ABBV) has disclosed Gross Profit for 14 consecutive years, with $12.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit rose 12.7% to $12.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $43.0 billion, a 8.94% increase, with the full-year FY2025 number at $43.0 billion, up 8.94% from a year prior.
  • Gross Profit was $12.1 billion for Q4 2025 at AbbVie, up from $10.5 billion in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $12.1 billion in Q4 2025 to a low of $7.4 billion in Q3 2023.
  • A 5-year average of $9.8 billion and a median of $9.9 billion in 2021 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: surged 40.54% in 2021, then dropped 23.98% in 2023.
  • AbbVie's Gross Profit stood at $10.6 billion in 2021, then increased by 3.64% to $11.0 billion in 2022, then fell by 21.5% to $8.6 billion in 2023, then increased by 24.53% to $10.7 billion in 2024, then increased by 12.7% to $12.1 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Gross Profit are $12.1 billion (Q4 2025), $10.5 billion (Q3 2025), and $11.1 billion (Q2 2025).